Ersodetug

DB18182InvestigationalProtein Based Therapies

Ersodetug: Overview.

Mechanism
Curator reviewed
Also known as
gamma2 heavy chain Homo sapiens (1-444) [VH(Homo sapiens IGHV3-20*01 (98.0%) -(IGHD)-IGHJ6*01 (93.8%), CDR-IMGT [8.8.11] (26-33.51-58.97-107)) (1-118) -Homo sapiens IGHG2*02 (100%), G2m23 CH2 M45.1 (CH1 (119-216), hinge 1-12 (217-228), CH2 M45.1 (279) (2 · immunoglobulin G2-kappa, anti-[Homo sapiens INSR (insulin receptor)], Homo sapiens monoclonal antibody, allosteric · Immunoglobulin G2, anti-(human insulin receptor) (human monoclonal RZ358 γ2-chain), disulfide with human monoclonal RZ358 κ-chain, dimer
Code names
RZ-358 · XOMA-358

Resolves to

Compound
UNIIQD87BSP58NCAS2410976-61-1
Targets
P06213INSR

What you can answer from here — as of July 08, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
5Clinical trialsPhase, status and sponsor resolved per trial
Sign in
3+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Ersodetug, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In